BIOLINERX     Print Page  Close Window

SEC filings
20-F
BIOLINERX LTD. filed this Form 20-F on 03/10/2016
Entire Document
 
97

 
 
E. Beneficial Ownership of Executive Officers and Directors
 
The following table sets forth information regarding the beneficial ownership of our outstanding ordinary shares as of March 1, 2016 of each of our directors and executive officers individually and as a group.
 
   
Number of
       
   
Shares
       
   
Beneficially
   
Percent of
 
   
Held
   
Class
 
             
Directors
           
             
Aharon Schwartz(1)                                                                               
    20,836       *  
Michael J. Anghel(2)                                                                               
    20,836       *  
Nurit Benjamini(3)                                                                               
    18,750       *  
B.J. Bormann(4)                                                                               
    19,586       *  
Raphael Hofstein(5)                                                                               
    40,836       *  
Avraham Molcho(6)                                                                               
    18,750       *  
Sandra Panem(7)                                                                               
    17,086          
                 
Executive officers
               
Kinneret Savitsky(8)                                                                               
    257,220       *  
Philip Serlin(9)                                                                               
    117,920       *  
David Malek(10)                                                                               
    70,500       *  
Arnon Aharon(11)                                                                               
    15,000       *  
Merril Gersten
           
All directors and executive officers as a group (11 persons)(12)
    617,320       1.1 %

   
*
Less than 1.0%.
     
(1)
Includes 20,836 ordinary shares issuable upon exercise of outstanding options within 60 days of March 1, 2016. Does not include 14,164 ordinary shares issuable upon exercise of outstanding options that are not exercisable within 60 days of March 1, 2016.
     
(2)
Includes 20,836 ordinary shares issuable upon exercise of outstanding options within 60 days of March 1, 2016. Does not include 14,164 ordinary shares issuable upon exercise of outstanding options that are not exercisable within 60 days of March 1, 2016.
     
(3)
Includes 18,750 ordinary shares issuable upon exercise of outstanding options within 60 days of March 1, 2016. Does not include 1,250 ordinary shares issuable upon exercise of outstanding options that are not exercisable within 60 days of March 1, 2016.
     
(4)
Includes 19,586 ordinary shares issuable upon exercise of outstanding options within 60 days of March 1, 2016. Does not include 15,414 ordinary shares issuable upon exercise of outstanding options that are not exercisable within 60 days of March 1, 2016.
     
(5)
Includes 40,836 ordinary shares issuable upon exercise of outstanding options within 60 days of March 1, 2016. Does not include 14,164 ordinary shares issuable upon exercise of outstanding options that are not exercisable within 60 days of March 1, 2016.
     
(6)
Includes 18,750 ordinary shares issuable upon exercise of outstanding options within 60 days of March 1, 2016. Does not include 1,250 ordinary shares issuable upon exercise of outstanding options that are not exercisable within 60 days of March 1, 2016.